Literature DB >> 15158092

Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia.

Srdan Verstovsek1, Francis J Giles, Susan O'Brien, Stefan Faderl, Hagop M Kantarjian, Michael J Keating, Maher Albitar.   

Abstract

We measured telomerase activity (TA) in bone marrow samples from 214 patients with CLL and correlated it with patients' characteristics and survival. In >50% of cases (126/214; 59%) no detectable TA was found. There was no difference in TA between previously treated (n = 153) and untreated (n = 61) patients (P = 0.4), or patients with various Rai (0-IV) stages (P = 0.85). TA correlated significantly with white blood cell and lymphocyte count (P = 0.02 and 0.01, respectively) but not with bone marrow cellularity, beta2-microglobulin (beta2M), or other patient characteristics. Patients who had no TA had slightly lower beta2M and lower lymphocyte counts (P = 0.5 and 0.04, respectively) as compared with patients with detectable TA. However, there was no correlation between TA and survival. This data suggests that TA may not play a significant role in the clinical behavior of CLL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15158092     DOI: 10.1016/j.leukres.2003.11.009

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  2 in total

1.  The evaluation of hTERT mRNA expression in acute leukemia children and 2 years follow-up of 40 cases.

Authors:  Ozgur Cogulu; Buket Kosova; Cumhur Gunduz; Emin Karaca; Serap Aksoylar; Ayse Erbay; Deniz Karapinar; Canan Vergin; Filiz Vural; Murat Tombuloglu; Nazan Cetingul; Ferda Ozkinay
Journal:  Int J Hematol       Date:  2008-02-22       Impact factor: 2.490

Review 2.  Telomeres and Telomerase in Hematopoietic Dysfunction: Prognostic Implications and Pharmacological Interventions.

Authors:  Theresa Vasko; Andrea Kaifie; Matthias B Stope; Thomas Kraus; Patrick Ziegler
Journal:  Int J Mol Sci       Date:  2017-10-28       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.